Want to see RYTM full AI Analyst Report?

Rhythm Pharmaceuticals (RYTM) Price & Analysis

616 Followers

RYTM Stock Chart & Stats

$102.10

-$0.56(-0.55%)

At close: Jul 24 4:00 PM EDT

$102.10

-$0.56(-0.55%)

Day’s Range― - ―

52-Week Range$74.50 - $122.20

Previous CloseN/A

Volume467.13K

Average Volume (3M)884.69K

Market Cap

$7.95B

Enterprise Value$7.51K

Total Cash (Recent Filing)$330.90M

Total Debt (Recent Filing)$3.68M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

Nov 10, 2026

EPS Estimate

-0.72

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.11

Shares Outstanding68,852,080

10 Day Avg. Volume531,086

30 Day Avg. Volume884,687

Financial Highlights & Ratios

PEG Ratio1.21

Price to Book (P/B)25.76

Price to Sales (P/S)36.66

P/FCF Ratio-59.64

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$142.47

Price Target Upside39.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)-3.01

Revenue Forecast (FY)$312.05M

Bulls Say, Bears Say

Bulls Say

High Product Margins & Revenue GrowthSustained high gross margins (~89–91%) and multi-year revenue growth (TTM ~$240M) indicate strong product-level economics and pricing power for IMCIVREE. These durable unit economics support reinvestment in commercialization and R&D while enabling scalable margin expansion as volumes grow.

Robust U.S. Commercial Launch TractionEarly adoption metrics—400+ start forms, ~300 activated prescribers and sequential Q2 sales growth—reflect durable commercial demand and prescriber engagement. Combined with growing payer coverage and repeat prescribers, this supports sustained revenue expansion as diagnosis and access improve over coming quarters.

Conservative Leverage And Multi-quarter Cash RunwayA sizeable cash balance and very low debt materially reduce near-term financing pressure and dilution risk, enabling execution of international launches and Phase III/III-like trials. This balance sheet cushion supports strategic optionality across commercialization and pipeline development over the next 2+ years.

Bears Say

Deep Ongoing UnprofitabilityDespite strong top-line growth, operating and net margins remain deeply negative (TTM operating margin ~-77%, net margin ~-86%), meaning the business still requires substantial cash to cover operating losses. Persistent unprofitability raises financing risk and delays self-sustaining cash generation absent margin or volume inflection.

High Operating Costs And SG&A GrowthRapidly expanding SG&A and sizeable non‑GAAP op‑ex guidance keep cash burn elevated even as sales grow. Continued high commercial and administrative spend pressures operating leverage, lengthens timeline to breakeven, and increases dependence on external funding if revenue scale or margin improvements lag expectations.

Diagnosis And Access ConstraintsStructural underdiagnosis and long specialty wait times limit addressable patient identification and time-to-paid therapy. Even with strong launch activity, durable uptake depends on clinician education and payer policy expansion; slow identification or access barriers could compress long-term growth trajectories.

Rhythm Pharmaceuticals News

Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital

RBC Capital raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $155 from $141 and keeps an...

15d ago

RYTM

Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord

Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $154 from $151 and keeps a Buy...

15d ago

RYTM

Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi

Citi analyst Samantha Semenkow raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $143 from $142 and...

15d ago

RYTM

Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens

Citizens raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $160 from $155 and keeps an Outperform...

15d ago

RYTM

Rhythm Pharmaceuticals’ RM-718 shows efficacy in Phase 2 obesity trial

Rhythm Pharmaceuticals (RYTM) announced preliminary results from the ongoing Phase 2 trial evaluating RM-718, Rhythm’s investigational once-weekly MC4R...

16d ago

RYTM

Rhythm Pharmaceuticals initiated with an Overweight at JPMorgan

JPMorgan analyst Priyanka Grover initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Overweight rating and $145 price target...

24d ago

RYTM

EMANATE Phase 3 Completion Puts Rhythm’s Genetic Obesity Strategy in Focus

Rhythm Pharmaceuticals ($RYTM) announced an update on their ongoing clinical study. The EMANATE phase 3 study, formally titled...

14d ago

RYTM

Imcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated

In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Rhythm...

15d ago

RYTM

Rhythm Pharmaceuticals Earnings Call Signals Momentum

Rhythm Pharmaceuticals (($RYTM)) has held its Q2 earnings call. Read on for the main highlights of the call....

15d ago

RYTM

Rhythm Pharmaceuticals Reports Promising Phase 2 Obesity Data

Rhythm Pharmaceuticals ( ($RYTM) ) just unveiled an announcement. Rhythm Pharmaceuticals reported strong commercial and clinical momentum for...

16d ago

RYTM

RYTM Earnings this Week: How Will it Perform?

Rhythm Pharmaceuticals (RYTM) is scheduled to report 2nd quarter earnings on 08/04/2026, before the market opens. Regarding Q2...

18d ago

RYTM

Analyst Reaffirms Buy on Rhythm as Imcivree Platform Expansion and Next‑Gen MC4R Assets Underpin Overweight Rating and $145 Price Target

Rhythm Pharmaceuticals (RYTM) has received a new Buy rating, initiated by J.P. Morgan analyst, . analyst has given...

24d ago

RYTM

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

WSW, NY, July 22nd, 2026, FinanceWire Ten billion dollars. That is what Vertex Pharmaceuticals (Nasdaq:VRTX) agreed to pay...

29d ago

PTN

CRNX

Rhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTM

Rhythm Pharmaceuticals ($RYTM) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals, Inc. is running an open-label...

1M ago

RYTM

RYTM FAQ

What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?

Rhythm Pharmaceuticals Inc lowest stock price was $74.50 and its highest was $122.20 in the past 12 months.

What is Rhythm Pharmaceuticals Inc’s market cap?

Rhythm Pharmaceuticals Inc’s market cap is $7.95B.

When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?

Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Nov 10, 2026 which is in 82 days.

How were Rhythm Pharmaceuticals Inc’s earnings last quarter?

Rhythm Pharmaceuticals Inc released its earnings results on Aug 04, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.807 by $0.077.

Is Rhythm Pharmaceuticals Inc overvalued?

According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rhythm Pharmaceuticals Inc pay dividends?

Rhythm Pharmaceuticals Inc does not currently pay dividends.

What is Rhythm Pharmaceuticals Inc’s EPS estimate?

Rhythm Pharmaceuticals Inc’s EPS estimate is -0.72.

How many shares outstanding does Rhythm Pharmaceuticals Inc have?

Rhythm Pharmaceuticals Inc has 68,852,080 shares outstanding.

What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?

Rhythm Pharmaceuticals Inc reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.807. Following the earnings report the stock price went up 2.919%.

Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in RYTM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rhythm Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

17.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.

Rhythm Pharmaceuticals (RYTM) Earnings & Revenues

Historic Earnings Reports

RYTM Company Deck

RYTM Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed a largely positive commercial and scientific momentum: robust early U.S. launch metrics for IMCIVREE in acquired hypothalamic obesity, 19% sequential product sales growth, encouraging RM-718 early efficacy comparable to existing MC4R agonists, NEJM coverage, and planned international rollouts (Japan and Europe). Key challenges include a one‑time France revenue charge, higher SG&A and continued GAAP losses, some tolerability-related discontinuations in RM-718, and ongoing diagnosis/access constraints that could temper uptake timing. On balance, the growth and pipeline derisking signals materially outweigh the near-term financial and operational headwinds.View all RYTM earnings summaries

RYTM Stock 12 Month Forecast

Average Price Target

$142.47

▲(39.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"80":"$80","161":"$161","100.25":"$100.3","120.5":"$120.5","140.75":"$140.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$160.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":142.46666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$142.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[80,100.25,120.5,140.75,161],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.25,103.92307692307692,108.59615384615384,113.26923076923077,117.9423076923077,122.61538461538461,127.28846153846155,131.96153846153845,136.6346153846154,141.30769230769232,145.98076923076923,150.65384615384616,155.3269230769231,{"y":160,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.25,102.57435897435897,105.89871794871794,109.22307692307692,112.5474358974359,115.87179487179488,119.19615384615385,122.52051282051282,125.84487179487179,129.16923076923078,132.49358974358975,135.81794871794872,139.1423076923077,{"y":142.46666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.25,99.6923076923077,100.13461538461539,100.57692307692308,101.01923076923077,101.46153846153847,101.90384615384616,102.34615384615384,102.78846153846153,103.23076923076923,103.67307692307692,104.11538461538461,104.5576923076923,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":88.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.94,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.81,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.87,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.41,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.25,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >